Home » News » July 2018

July, 2018

Swanson Reed – R&D Legislative Amendment Submission

July 25th, 2018

The Australian Government announced a reform of the R&D Tax Incentive program as part of the 2018-19 Federal Budget. Swanson Reed is of the view that stable and generous support for R&D must be maintained to give companies the confidence to invest in long-term innovation strategies. We have provided feedback in response to the draft legislation of amendments to the Research and Development Tax Incentive.  To read our submission to the Treasury, please click the link below: Swanson Reed – […]

Read More

Neurotechnology company receives $35 million R&D funding to cure sleep problems

July 11th, 2018

Dreem is a neurotechnology company that is currently working on a state of the art product which could potentially end sleeping problems and enhance people’s quality of rest during the night. The company has just been granted $35 million R&D funding to accelerate its latest product and invest into further research and development to advance its technology. The product is a ‘Dreem headband’ which monitors brain activity to track sleep accurately and use auditory stimulation as a medium to help […]

Read More

3D Printing is changing the construction industry

July 9th, 2018

The construction industry has traditionally been very conservative and at times slow to innovate, however a change seems to be occurring. The industry is now embracing more innovative technology and the introduction of 3D printing buildings and homes is one current example of this. The 3D buildings are made by a very large 3D printer that consists of a robotic base which has 360 degrees of motion and a smaller arm that prints out various building materials. This technology holds […]

Read More

Draft Legislation Released for R&D Tax Incentive

July 3rd, 2018

The Government announced on 8 May 2018 that the Research and Development Tax Incentive (R&DTI) would be reformed and that changes would apply from 1 July 2018. Draft legislation has been released regarding amendments to the R&DTI. Stakeholder feedback is encouraged and responses can be submitted until 26 July 2018. Changes to the Bill include: Increasing the R&D expenditure threshold from $100 to $150 million; Introducing a $4 million cap on annual cash refunds (the cap excludes clinical trials). Refunds over […]

Read More

Categories

Archives